Notably, previous works have reported a significant upregulation of JMJD6 in breast cancer tissues, and specific small molecule inhibitors targeting JMJD6 have exhibited a reduction in the proliferative capacity of breast cancer cells both in vitro and in vivo [35–37]. Here, JMJD6 is linked to breast cancer.